https://www.selleckchem.com/products/jh-re-06.html
Advancements in programmable DNA-binding proteins (DBDs) that target the genome, such as zinc fingers, transcription activator-like effectors, and Cas9, have broadened drug target design beyond traditional protein substrates. Effective delivery methodologies remain a major barrier in targeting the central nervous system. Currently, adeno-associated virus is the most well-validated delivery system for the delivery of DBDs towards the central nervous with multiple, on-going clinical trials. While effective in transducing neuronal cells,
Мне нравится
Комментарий
Перепост
